BioTech IP Review

Patent Number: US 11,897,915 B2
Filing Date: January 3, 2024
Publication/Issue Date: June 6, 2024
Assignee: Rubedo Life Sciences, Inc.
Inventors: Paul Keitz, Gus Bergnes, Mark A. Gallop, Marco Quarta

---

What This Patent Covers

Overview:
This granted patent protects a new class of sugar‑derived chemical compounds that serve as intermediates in the synthesis of senolytic agents — drugs designed to selectively eliminate senescent cells, which are dysfunctional “zombie” cells that accumulate with age and contribute to chronic inflammation and many age‑related diseases.

Key aspects claimed in the patent:

• Novel sugar derivative compounds that can be used as building blocks in the preparation of next‑generation senolytic small molecules.
• Methods of making senolytic agents from these sugar derivatives, enabling pharmaceutical companies to produce targeted therapies for diseases driven by cellular senescence.
• Therapeutic use: These derivatives and the compounds derived from them can be formulated into pharmaceutical compositions aimed at treating or preventing pathologies associated with senescent cell accumulation, including inflammation, fibrosis, metabolic dysfunction, and other degenerative conditions linked to aging.

---

Why Important

• Strategic commercial relevance: Senolytic therapies — designed to clear senescent cells — are a high‑interest area in aging and chronic disease biotechnology, with potential applications across dermatology, pulmonary fibrosis, metabolic disease, and more. Rubedo’s patent lays groundwork for proprietary molecules in this space.
• Foundation for drug development: The sugar derivatives covered here are intermediate building blocks that could underpin multiple therapeutic candidates in Rubedo’s pipeline, including small molecules targeting pathological aging cells.
• IP protection for pipeline R&D: By protecting these intermediates and synthetic uses, Rubedo strengthens its intellectual property estate around senolytic agents — an emerging therapeutic class with a large potential market in longevity and age‑related disease treatment.

---

Summary

U.S. Patent No. 11,897,915 B2, titled Sugar derivatives and uses thereof to prepare novel senolytic agents protects novel sugar‑derived chemical intermediates and methods for using them to make senolytic drugs that selectively eliminate senescent cells tied to aging and chronic disease. This patent is materially important to Rubedo Life Sciences because it contributes core intellectual property supporting the company’s pipeline of small‑molecule senolytic therapeutics.